Remote pharmaceutical care for patients with rheumatoid arthritis and psoriasis

  • PDF / 615,349 Bytes
  • 10 Pages / 595.276 x 790.866 pts Page_size
  • 29 Downloads / 199 Views

DOWNLOAD

REPORT


RESEARCH ARTICLE

Remote pharmaceutical care for patients with rheumatoid arthritis and psoriasis V. Martínez‑Santana1 · A. Boix‑Montañés2 · E. Fernández‑Cañabate2 · B. González‑Melarde2 · N. Miserachs‑Aranda2 · P. Modamio‑Charles3 · C. Fernández‑Lastra3 · E. Mariño‑Hernández3 Received: 3 November 2019 / Accepted: 11 November 2020 © Springer Nature Switzerland AG 2020

Abstract BackgroundAccess to drugs with hospital-restricted dispensation, such as those for patients with rheumatoid arthritis or psoriasis, is regulated by healthcare policy. These drugs have the greatest cost-effective impact on the healthcare system. This is why a model for Pharmaceutical Care based on follow-up teleconsultations was defined in our hospital to improve patient well-being. Objective To evaluate clinical changes on patients when our remote Pharmaceutical Care model is applied and describe the work carried out by pharmacists when applying it. Setting Pharmacy Department of a Hospital in Barcelona, Spain. Method Cross-sectional observational study of the remote Pharmaceutical Care model developed by Clinical Pharmacists. All patients diagnosed with psoriasis or rheumatoid arthritis who were receiving active treatment with Hospital/Specialist only drugs, during the period from May to December 2018, were included. Main outcome measures The corresponding healthcare activity was recorded and to determine the utility of the model, the clinical response to treatment of patients included in the study was recorded. Results The implementation of teleconsultation is statistically related to the biological treatment response of patients with psoriasis (p = 0.006) and rheumatoid arthritis (p = 0.019). In those patients the healthcare activity of calculating and/or recording clinical variables of effectiveness/safety is statistically associated to biological treatment response (65.62% vs 35%, p = 0.015 and 73.14% vs 53.26%, p = 0.003). Conclusions The implementation of the model described lends added value to traditional pharmacotherapeutic management of biological treatments in patients with rheumatoid arthritis and psoriasis since response is improved but patient well-being is not diminished. Keywords  Clinical pharmacist · Immune-mediated diseases · Pharmaceutical care · Psoriasis · Rheumatoid arthritis · Spain · Treatment

Impacts on practice • Teleconsultations have demonstrated their utility in all

aspects of Pharmaceutical Care and should be promoted. • Undertaking remote consultations could impact the patient’s quality of life whilst maintaining effective pharmaco-therapeutic levels. * V. Martínez‑Santana [email protected] 1



Pharmacy Department, Institut Guttmann, Barcelona, Spain

2



Pharmacy Department, Fundació Hospital de L’Esperit Sant, Barcelona, Spain

3

Clinical Pharmacy and Pharmacotherapy Unit, Pharmacy and Pharmaceutical Technology Deparment, Faculty of Pharmacy, Universidad de Barcelona, Barcelona, Spain



• Through teleconsultation professionals develop their

pharmaceutical activity in a flexible way.

• Descri